The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Tuberous Sclerosis Complex Research Program -- Exploration-Hypothesis Development Award
The TSCRP Exploration – Hypothesis Development Award mechanism was first offered in FY02. Since then, 194 Exploration – Hypothesis Development Award applications have been received, and 43 have been recommended for funding.
The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a wellformulated, testable hypothesis based on strong scientific rationale and study design.
• Pre-Application Deadline: The pre-application deadline has been extended to July 9 2019:
• Application Submission Deadline:
May 9, 2019
Areas of Interest
The mission of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public. Within this context, the FY19 TSCRP encourages applications that specifically address the critical needs of the TSC community in one or more of the following Focus Areas:
- Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
- Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
- Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
- Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization
If the proposed research project does not address one or more of the FY19 TSCRP Focus Areas, justification that the proposed research project addresses an important problem or unmet need related to TSC research and/or patient care should be provided.
Investigators at all academic levels (or equivalent), including postdoctoral fellows, are eligible to submit applications. An eligible Principal Investigator, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Exploration – Hypothesis Development Award will not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.